Potential to Address a Broad Patient Population:

Our AAVHSCs could target a broad patient population due to the low frequency of preexisting neutralizing antibodies.*

*Ellsworth JL, O’Callaghan M, Rubin H, et al. Low seroprevalence of neutralizing antibodies targeting two Clade F AAV in humans. Hum Gen Ther Clin Dev, 2018: 60-67.